Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ciprofloxacin
Drug ID BADD_D00471
Description Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics.[A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] The first ciprofloxacin containing product was FDA approved on 22 October 1987.[L6463]
Indications and Usage Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478] A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493] A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475] A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]
Marketing Status approved; investigational
ATC Code J01MA02; S01AE03; S02AA15; S03AA07
DrugBank ID DB00537
KEGG ID D00186
MeSH ID D002939
PubChem ID 2764
TTD Drug ID D0O1WX
NDC Product Code 72789-118; 82982-025; 42708-146; 67296-1848; 0409-2300; 70518-3063; 70985-008; 71610-081; 76420-214; 12527-0537; 16252-516; 52286-0014; 16571-412; 50090-5483; 55111-126; 60429-042; 61919-795; 62135-392; 68071-1893; 68071-2913; 69315-308; 71335-2097; 72189-300; 0615-8367; 72789-193; 53069-0680; 36000-297; 0143-9929; 45865-471; 50090-4220; 55111-125; 62135-393; 63187-001; 66992-450; 67296-1269; 68071-2525; 68788-7905; 68788-9012; 70985-011; 71335-1867; 71335-2054; 63187-017; 63629-7786; 66267-919; 68788-7500; 71205-749; 71335-1640; 0904-7083; 16252-514; 36000-009; 0143-9927; 55154-3368; 55700-737; 58657-676; 63629-1724; 63629-5154; 67296-1097; 67296-1389; 67296-1479; 68071-3013; 68788-9006; 70518-2390; 72789-124; 0904-7243; 42708-088; 45865-530; 53002-2642; 53002-2790; 55111-128; 58657-675; 63629-1326; 67296-1575; 0409-3300; 0409-4777; 70518-0693; 70934-316; 72789-125; 16571-413; 45865-772; 53002-2640; 63629-3868; 67296-0237; 67296-1318; 68788-8200; 72189-242; 80425-0164; 55111-015; 25021-192; 35356-733; 0143-9928; 50090-4217; 61919-371; 63187-990; 68071-4201; 0904-6378; 58032-0127; 16571-411; 25021-114; 36000-008; 43063-547; 43063-767; 51655-086; 54348-662; 54348-663; 55111-127; 60760-815; 61919-361; 63187-142; 63629-7950; 68788-9280; 70518-2837; 70985-012; 71335-1393; 16252-515; 42195-550; 43063-410; 43063-869; 60760-676; 68071-2267; 68071-2269; 68788-7864; 68788-9024; 70518-3417; 71205-300; 71335-0070; 71335-0408; 72189-304; 72189-323; 72789-108; 12527-0540; 36000-298; 42708-002; 45865-994; 50090-5621; 50419-773; 50419-777; 51655-118; 51655-490; 53002-2791
UNII 5E8K9I0O4U
Synonyms Ciprofloxacin | Ciprofloxacin Hydrochloride Anhydrous | Anhydrous, Ciprofloxacin Hydrochloride | Hydrochloride Anhydrous, Ciprofloxacin | Cipro | Ciprofloxacin Hydrochloride | Hydrochloride, Ciprofloxacin | Ciprofloxacin Monohydrochloride Monohydrate | Monohydrate, Ciprofloxacin Monohydrochloride | Monohydrochloride Monohydrate, Ciprofloxacin | Bay-09867 | Bay 09867 | Bay09867 | Ciprinol
Chemical Information
Molecular Formula C17H18FN3O3
CAS Registry Number 85721-33-1
SMILES C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood potassium increased13.11.01.011--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Blood urea decreased13.13.01.017--Not Available
Blood urea increased13.13.01.006--Not Available
Blood uric acid decreased13.02.04.004--Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Bone pain15.02.01.001--
Bradycardia02.03.02.002--Not Available
Breast pain21.05.05.003--
Bronchospasm22.03.01.004; 10.01.03.012--
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Bursitis12.04.03.010; 15.04.01.001--Not Available
Cardiac arrest02.03.04.001--
Cardiac murmur13.14.01.001--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Carpal tunnel syndrome17.09.02.001--Not Available
Cerebral thrombosis24.01.04.003; 17.08.01.006--Not Available
Cerebrovascular disorder24.03.05.002; 17.08.02.002--Not Available
Chest discomfort22.12.02.002; 02.02.02.009; 08.01.08.019--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000021%Not Available
Chills15.05.03.016; 08.01.09.0010.000021%
Choking22.12.03.003--Not Available
Chromatopsia06.02.05.001--Not Available
Chromaturia20.02.01.002--
Circulatory collapse24.06.02.001--Not Available
Clostridium difficile colitis11.02.02.004; 07.19.01.004--Not Available
Coagulopathy01.01.02.001--Not Available
Cold sweat08.01.03.024; 23.02.03.002--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene